Reuters logo
BRIEF-ArgenX launches Phase II proof-of-concept clinical trial of ARGX-113 for treatment of pemphigus vulgaris
September 26, 2017 / 5:12 AM / 22 days ago

BRIEF-ArgenX launches Phase II proof-of-concept clinical trial of ARGX-113 for treatment of pemphigus vulgaris

Sept 26 (Reuters) - ARGENX NV:

* ARGENX LAUNCHES PHASE II PROOF-OF-CONCEPT CLINICAL TRIAL OF ARGX-113 FOR THE TREATMENT OF PEMPHIGUS VULGARIS

* ‍INTERIM DATA EXPECTED IN H2 2018​

* ‍TOPLINE DATE FOR MG AND ITP ARE EXPECTED IN Q1 AND SECOND HALF OF 2018, RESPECTIVELY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below